Functional iron deficiency anemia was associated with higher mortality in chronic kidney disease patients: the NHANES III follow-up study Authors: Weiyuan Gong, Jiaofeng Huang, Tongying Zhu, Su Lin, Chuanming Hao, Min Zhang Published: 2023 ABSTRACT AbstractAnemia, a common complication of chronic kidney disease (CKD), is associated with poor prognosis. However, it is not completely clear whether this association is caused by anemia per se or other comorbidities. Whether different types of iron deficiency anemia can predict the outcomes of CKD remains unclear. The dataset from NHANES III was analyzed and Cox multivariate regression models and propensity score matching (PSM) method were used to evaluate the effect of anemia on mortality. Of 4103 patients with CKD, 14.6% had anemia. Among those with anemia, 38.8% had absolute iron deficiency (AID), and 19.8% had functional iron deficiency (FID). During the median follow-up time of 13.8 years, 2964 deaths and 804 cardiovascular deaths were observed. Anemia was robustly associated with a high risk of all-cause mortality in CKD patients after adjusting covariates by two multivariate regression models (Model 1: HR = 1.485, 95%CI:1.340–1.647, p < 0.001; Model 2: HR = 1.391, 95%CI:1.250–1.546, p < 0.001). In the PSM cohort, anemia was still an independent risk factor for all-cause mortality (Model 1: HR = 1.443, 95%CI: 1.256–1.656, p < 0.001; Model 2: HR = 1.357, 95%CI:1.177–1.564, p < 0.001). In the CKD population, anemia patients with FID had the highest risk of mortality than the other anemia groups (p < 0.05), while AID had a mortality rate similar to those without anemia (p > 0.05). In conclusion, anemia was associated with a worse prognosis in patients with CKD, which may be attributed to the higher mortality risk of FID rather than AID. AID wasn’t associated with a higher mortality rate compared with CKD patients without anemia. Introduction Chronic kidney disease (CKD) is a public health problem. The occurrence of comorbidities in CKD patients has been suggested to contribute to increased mortality [1, 2]. Anemia is one of the complications of CKD and its prevalence increases with the severity of CKD [3, 4]. Anemia in CKD is associated with reduced health-related quality of life, higher risk of disease progression, and increased cardiovascular and all-cause mortality [5–7]. However, there is a paucity of clear data that demonstrates the effect of anemia correction on cardiovascular outcomes. Impaired iron availability for erythropoiesis is an important cause of CKD anemia, which may be due to a true paucity of iron storage (absolute iron deficiency, AID) or a relative functional iron deficiency (FID). The FID is associated with underlying inflammation, which impairs iron mobilization and utilization [8]. Importantly, inflammation is also associated with increased cardiovascular events [9]. Several studies have examined the consequences of iron deficiency anemia in the dialysis population [10], but limited data exists on the correlation of absolute and functional iron deficiency with outcomes in non-dialysis-dependent CKD. Therefore, in this prospective cohort study, we investigated the prevalence of anemia, including AID, FID, and other causes of anemia, among patients with non-dialysis-dependent CKD. We also explored the association of different types of iron deficiency anemia with cardiovascular-related and all-cause mortality in this population. Methods Participants and ethics The Third National Health and Nutrition Examination Study (NHANES III) is a national, cross-sectional inhabitant survey conducted by the National Center for Health Statistics of the United States from 1984 to 1994 to gather data on Americans’ physical fitness and nutritional status. The adopted profile of survey participants up to December 2015 was extracted from the morality dataset: https://www.Cdc.gov/nchs/facts-linkage/mortality.Htm. The NCHS Ethic Review Board confirmed the poll, and each respondent provided written informed permission. The study included all cases with available results of renal function tests and anemia-relevant tests. Patients with missing key data, such as survival data, renal function data, blood routine examination, and iron-related parameters were excluded. The flow chart is shown in Figure 1. The flowchart of case selection. Definition Anemia was defined as Hemoglobin (Hb) concentration < 13.0 g/dL in males and < 12.0 g/dL in females according to WHO criteria. AID was defined as transferrin saturation (TSAT) < 20% and ferritin <100 ng/mL [11]. FID was defined as TSAT < 20% and ferritin 100–500 ng/mL. Patients with TSAT ≥ 20% were classified as a separate group, representing the anemia group with other causes. Estimated glomerular filtration rate (eGFR) was calculated using the 2009 CKD-EPI eGFR formula [12]: eGFR = 141 × min (SCr/κ, 1)α × max (SCr/κ, 1)−1.209 × 0.993Age × (1.018 if female) × (1.159 if Black); κ = 0.7 (females) or 0.9 (males); α = −0.329 (females) or −0.411 (males), where SCr stands for serum creatinine (in mg/dL) and age stands for age in years. CKD was defined as either decreased eGFR (<60 mL/min/1.73m2) and/or abnormal albuminuria and/or overt proteinuria, according to the Kidney Disease: Improving Global Outcome (KIDGO) 2012 Practice guideline for CKD [13]. The blood pressure measurements were used to identify hypertension: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg, a significant history of hypertension, and/or under-treatment of hypertension [14]. Diabetes was defined as having a history of diabetes, fasting blood glucose (FBG) ≥ 7.0 mmol/L, or glycated hemoglobin (HbA1c) ≥ 6.5% or 2-h postprandial glucose ≥ 11.0 mmol/L, current use of insulin or taking medication for lower blood glucose. Body mass index (BMI, kg/m2) was calculated as the weight divided by the square of the height. Statistical analysis By using R studio (3.6.2), statistical analysis is performed. Continuous variables were given as mean ± standard deviation or median (interquartile stages), and compared with the Student’s t-test or Mann–Whitney test. Categorical variables were represented as counts (percentages) and compared with the Chi-squared test. Cox Proportional Hazards Model was used to determine HRs with 95% CI for anemia and mortality. The propensity score matching (PSM) method was used to select matched cases from anemia and non-anemia groups, thus minimizing the bias in estimating the impact of anemia on mortality. PSM is a statistical technique that accounts for confounding variables in observational studies. In this retrospective cohort study, PSM involves two steps. First, the propensity scores were generated using a logistic regression model from the following variables: age, gender, and serum creatinine. Second, the derived propensity scores are used to match anemia and non-anemia patients using the nearest neighbor 1:1 matching method. A total of 1146 patients were matched using PSM analysis. All statistical tests were 2-sided, and a p-value < 0.05 was considered significant. Results Baseline characteristics of the study population Among 15,322 participants, 4103 (26.8%) were with CKD. The baseline characteristics of these CKD patients with or without anemia are shown in Table 1. There were 42.5% males and the mean age was 64.2 ± 17.5 years old. The prevalence of diabetes was 28.8% and hypertension was 73.9%. The mean hemoglobin concentration was 137.6 ± 15.1 g/L. Anemia was diagnosed in 14.4% (n = 590) of the patients with CKD. Of those with anemia, 38.8% (n = 229) had absolute iron deficiency (AID), 19.8% (n = 117) had functional iron deficiency (FID) and 41.4% (n = 244) had other causes of anemia. The serum creatinine, serum C-reactive protein (CRP), and urine albuminuria creatinine ratio (ACR) were significantly higher in the anemia group (p < 0.001) (Table 1). The prevalence of advanced CKD (CKD 4–5 stages) was also higher in the anemia group (p < 0.001) Table 1.The characteristics of CKD patients with or without anemia before PSM.VariablesTotalNon-anemiaAnemiaP N 41033513590 Male, n (%)1743 (42.5)1486 (42.3)257 (43.6)0.598Age (year)64.2 ± 17.564.2 ± 17.164.4 ± 19.30.819Race, n (%) <0.001Non-Hispanic white2282 (55.6)2050 (58.4)232 (39.3) Non-Hispanic black913 (22.3)673 (19.2)240 (40.7) Mexican-American764 (18.6)663 (18.9)101 (17.1) Other144 (3.5)127 (3.6)17 (2.9) DM, n (%)1183 (28.8)1002 (28.5)181 (30.7)0.308Hypertension, n (%)3034 (73.9)2603 (74.1)431 (73.1)0.628BMI (kg/m2)27.6 ± 5.727.7 ± 5.726.7 ± 6.0<0.001Hb (g/L)137.6 ± 15.1141.5 ± 11.9114.6 ± 10.6<0.001FBG (mmol/L)6.3 ± 3.06.3 ± 3.06.3 ± 3.30.734Cholesterol (mmol/L)5.7 ± 1.25.7 ± 1.25.3 ± 1.3<0.001Triglyceride (mmol/L)1.9 ± 1.51.9 ± 1.51.7 ± 1.5<0.001Scr (µmol/L)109.9 ± 39.6106.5 ± 26.3129.7 ± 79.7<0.001GFR (mL/min/1.73m2)58.9 ± 19.659.4 ± 18.755.8 ± 24.4<0.001CKD stages, n (%) <0.001 1366 (8.9)298 (8.5)68 (11.5) 2855 (20.8)752 (21.4)103 (17.5) 32762 (67.3)2402 (68.4)360 (61.0) 4101 (2.5)58 (1.7)43 (7.3) 519 (0.5)3 (0.1)16 (2.7) ACR ≥ 3 mg/mmoL, n (%)1982 (48.3)1643 (46.8)339 (57.5)<0.001ACR (mg/mmoL)2.64 (0.79, 7.13)2.37 (0.76, 6.65)3.60 (1.00, 11.2)<0.001Vitamin D (nmol/L)55.1 ± 20.156.0 ± 20.050.0 ± 20.0<0.001CRP (mg/dL)0.6 ± 0.90.5 ± 0.80.7 ± 1.2<0.001Iron (ug/dL)13.79 (10.39,17.91)14.33 (11.10,18.45)10.48 (7.52,14.15)<0.001TSAT (%)22.6 (17.0,29.9)23.4 (17.9,30.6)18.3 (12.2,24.6)<0.001Ferritin (ng/mL)105.0 (52.0,195.0)107.0 (56.0,196.0)82.5 (24.0,189.0)<0.001Anemia type, n (%) <0.001 Other anemia244 (5.9)0 (0)244 (41.4) FID117 (2.9)0 (0)117 (19.8) AID229 (5.6)0 (0)229 (38.8) Data presented as mean ± SD, median (interquartile range), or %. DM, diabetes; BMI, body mass index; Hb, Hemoglobin; FBG, fasting blood glucose; Scr, serum creatinine; GFR, glomerular filtration rate; CKD, chronic kidney disease. ACR, albuminuria creatinine ratio; CRP, C-reactive protein; TSAT, transferrin saturation; FID, functional iron deficiency; AID, absolute iron deficiency. The characteristics of CKD patients with or without anemia before PSM. Data presented as mean ± SD, median (interquartile range), or %. DM, diabetes; BMI, body mass index; Hb, Hemoglobin; FBG, fasting blood glucose; Scr, serum creatinine; GFR, glomerular filtration rate; CKD, chronic kidney disease. ACR, albuminuria creatinine ratio; CRP, C-reactive protein; TSAT, transferrin saturation; FID, functional iron deficiency; AID, absolute iron deficiency. The association between anemia and mortality in CKD before propensity score matching (PSM) The median follow-up time was 13.8 (7.0, 22.3) years with 58,557 person-years of follow-up. During this period, 2964 (72.2%, 50.6/1000 person-year) death events were observed, with 804 deaths caused by cardiovascular diseases. The Kaplan–Meier curve revealed anemia was associated with significantly higher mortality compared to non-anemia patients (all-cause mortality, Figure 2(A), p < 0.001; cardiovascular mortality, Figure 2(B), p = 0.045). Kaplan–Meier curves of all-cause mortality and cardiovascular mortality in CKD patients. (A) 25-year all-cause mortality, p < 0.001; (B) 25-year cardiovascular mortality, p = 0.045; (C) 25-year all-cause mortality of 573 paired patients, matching for eGFR, age, and gender, p < 0.001; (D) 25-year cardiovascular mortality of 573 paired patients, matching for eGFR, age, and gender, p > 0.05. We next adjusted for potential confounding factors in two different multivariate regression models to further explore the effect of anemia on the prognosis of CKD. Model 1 adjusted for age, gender, race, diabetes, and hypertension, and model 2 additionally adjusted for BMI, FBG, cholesterol, triglyceride, GFR, ACR, Vitamin D, CRP, and ferritin. The result of the multivariate Cox analysis is shown in Table 2. Anemia was robustly associated with a higher risk of all-cause mortality in CKD patients after adjusting these covariates (Model 1: HR =1.485, 95%CI: 1.340–1.647, p < 0.001; Model 2: HR = 1.391, 95%CI: 1.250–1.546, p < 0.001). The result of a multivariate Cox analysis about the effect of anemia on cardiovascular death is shown in Supplementary Table 1, showing no significant association between anemia and cardiovascular death after fully adjusting for potential confounders. Table 2.Multivariate COX regression of 25-year survival in CKD before PSM.VariablesHR (95% CI)PModel 1 Anemia1.485 (1.340–1.647)<0.001Male1.481 (1.378–1.593)<0.001Age1.073 (1.070–1.077)<0.001Race Non-Hispanic white1.000 Non-Hispanic black1.026 (0.931–1.131)0.603 Mexican-American0.945 (0.852–1.048)0.283 Other0.622 (0.495–0.781)<0.001DM1.461 (1.351–1.581)<0.001Hypertension1.193 (1.085–1.311)<0.001Model 2 Anemia1.391 (1.250–1.546)<0.001Male1.527 (1.411–1.652)<0.001Age1.072 (1.067–1.076)<0.001Race Non-Hispanic white1.000 Non-Hispanic black0.960 (0.866–1.065)0.441 Mexican-American0.845 (0.756–0.944)0.003 Other0.610 (0.486–0.767)<0.001DM1.283 (1.170–1.407)<0.001Hypertension1.191 (1.081–1.311)<0.001BMI (kg/m2)0.988 (0.980–0.995)0.002FBG (mmol/L)1.030 (1.016–1.044)<0.001Cholesterol (mmol/L)1.011 (0.977–1.045)0.540Triglyceride (mmol/L)1.021 (0.995–1.048)0.115GFR (mL/min/1.73m2)0.998 (0.995–1.001)0.222ACR (mg/mmoL)1.001 (1.001–1.002)<0.001Vitamin D (nmol/L)0.995 (0.993–0.997)<0.001CRP (mg/dL)1.130 (1.089–1.173)<0.001Ferritin ≥ 100 (ng/mL)1.008 (0.935–1.088)0.828Data presented as HR (95% CI). DM, diabetes; BMI, body mass index; FBG, fasting blood glucose; GFR, glomerular filtration rate; ACR: albuminuria creatinine ratio; CRP: C-reactive protein. Multivariate COX regression of 25-year survival in CKD before PSM. Data presented as HR (95% CI). DM, diabetes; BMI, body mass index; FBG, fasting blood glucose; GFR, glomerular filtration rate; ACR: albuminuria creatinine ratio; CRP: C-reactive protein. The association between anemia and mortality in CKD after PSM As anemia is closely related to the severity of CKD, we used the PSM method to select matched cases from the anemia and non-anemia groups to investigate the impact of anemia on the mortality of CKD patients. By matching eGFR, age, and gender, 573 pairs of non-anemia and anemia cases were selected. The baseline characteristics of the two groups are shown in Table 3. The sex, age, and GFR were comparable between groups after PSM. The results showed that anemia was still an independent risk factor for all-cause mortality in CKD patients (Model 1: HR = 1.443, 95%CI: 1.256–1.656, p < 0.001; Model 2: HR = 1.357, 95%CI: 1.177–1.564, p < 0.001, Figure 2(C), p < 0.001). However, in the PSM cohort, anemia was not significantly associated with cardiovascular mortality (Figure 2(D), p = 0.46). The result of the multivariate Cox analysis about the effect of anemia on cardiovascular death in the PSM cohort is shown in Supplementary Table 2. The results showed that anemia was not independently associated with a higher risk of cardiovascular mortality (p > 0.05). Table 3.The characteristics of CKD patients with or without anemia after PSM.VariablesTotalNon-anemiaAnemiaP N 1146573573 Male, n (%)492 (42.9)245 (42.8)247 (43.1)0.952Age (year)63.6 ± 19.562.5 ± 19.664.7 ± 19.30.062Race, n (%) <0.001 Non-Hispanic white525 (45.8)293 (51.1)232 (40.5) Non-Hispanic black387 (33.8)156 (27.2)231 (40.3) Mexican-American198 (17.3)105 (18.3)93 (16.2) Other36 (3.1)19 (3.3)17 (3.0) DM, n (%)340 (29.7)166 (29)174 (30.4)0.651Hypertension, n (%)836 (72.9)420 (73.3)416 (72.6)0.842BMI (kg/m2)27.4 ± 628 ± 5.826.7 ± 6<0.001Hb (g/L)127.3 ± 16.9139.8 ± 12.4114.8 ± 10.3<0.001FBG (mmol/L)6.3 ± 3.36.4 ± 3.46.2 ± 3.20.325Cholesterol (mmol/L)5.5 ± 1.35.7 ± 1.35.3 ± 1.3<0.001Triglyceride (mmol/L)1.8 ± 1.41.9 ± 1.61.7 ± 1.20.004Scr (µmol/L)117.3 ± 44.4113.7 ± 35.5120.9 ± 51.50.006GFR (mL/min/1.73m2)57.8 ± 22.858.5 ± 21.857 ± 23.70.242CKD stages, n (%) 0.107 1127 (11.1)59 (10.3)68 (11.9) 2215 (18.8)112 (19.5)103 (18) 3737 (64.3)378 (66)359 (62.7) 458 (5.1)22 (3.8)36 (6.3) 59 (0.8)2 (0.3)7 (1.2) eGFR < 60, n (%)804 (70.2)402 (70.2)402 (70.2)1.000ACR ≥ 3 mg/mmoL, n (%)619 (54)295 (51.5)324 (56.5)0.097ACR (mg/mmoL)24.5 ± 93.618.2 ± 59.830.8 ± 117.90.022Vitamin D (nmol/L)52.5 ± 20.655 ± 20.950 ± 20.1<0.001CRP (mg/dL)0.7 ± 10.6 ± 0.80.7 ± 1.20.069Iron (ug/dL)11.82 (8.78, 15.58)13.25 (10.21, 17.01)10.39 (7.52, 14.15)<0.001TSAT (%)19.80 (14.60, 26.90)21.60 (16.62, 28.46)18.10 (12.10, 24.50)<0.001Ferritin (ng/mL)92.00 (36.00, 181.00)97.00 (47.25, 177.75)83.00 (23.00, 183.00)0.003AID, n (%)365 (31.8)142 (24.8)223 (38.9)<0.001FID, n (%)204 (17.8)96 (16.8)108 (18.8)0.396Ferritin > 500, n (%)11 (1)3 (0.5)8 (1.4)0.226Anemia type, n (%) <0.001 Non-anemia573 (50)573 (100)0 (0) Other anemia234 (20.4)0 (0)234 (40.8) FID116 (10.1)0 (0)116 (20.2) AID223 (19.5)0 (0)223 (38.9) Data presented as mean ± SD, median (interquartile range), or %. DM: diabetes; BMI: body mass index; Hb: Hemoglobin; FBG: fasting blood glucose; Scr: serum creatinine; GFR: glomerular filtration rate; CKD: chronic kidney disease. ACR: albuminuria creatinine ratio; CRP: C-reactive protein; TSAT: transferrin saturation; FID: functional iron deficiency; AID: absolute iron deficiency. The characteristics of CKD patients with or without anemia after PSM. Data presented as mean ± SD, median (interquartile range), or %. DM: diabetes; BMI: body mass index; Hb: Hemoglobin; FBG: fasting blood glucose; Scr: serum creatinine; GFR: glomerular filtration rate; CKD: chronic kidney disease. ACR: albuminuria creatinine ratio; CRP: C-reactive protein; TSAT: transferrin saturation; FID: functional iron deficiency; AID: absolute iron deficiency. Table 4.Multivariate COX regression of 25-year survival in CKD after PSM.VariablesHR (95% CI) p Model 1 Anemia1.443 (1.256–1.656)<0.001Male1.517 (1.321–1.742)<0.001Age1.064 (1.058–1.071)<0.001Race Non-Hispanic white1.000 Non-Hispanic black0.822 (0.699–0.967)0.018 Mexican-American0.854 (0.692–1.055)0.144 Other0.395 (0.248–0.627)<0.001DM1.370 (1.181–1.590)<0.001Hypertension1.186 (0.988–1.422)0.067Model 2 Anemia1.357 (1.177–1.564)<0.001Male1.481 (1.275–1.720)<0.001Age1.059 (1.051–1.066)<0.001Race Non-Hispanic white1.000 Non-Hispanic black0.833 (0.697–0.994)0.043 Mexican-American0.816 (0.652–1.022)0.077 Other0.395 (0.248–0.629)<0.001DM1.149 (0.963–1.370)0.124Hypertension1.225 (1.015–1.478)0.034BMI (kg/m2)0.976 (0.962–0.991)0.002FBG (mmol/L)1.026 (1.001–1.051)0.040Cholesterol (mmol/L)0.988 (0.929–1.050)0.686Triglyceride (mmol/L)1.076 (1.015–1.141)0.014GFR (mL/min/1.73 m2)0.991 (0.986–0.997)0.002ACR (mg/mmoL)1.001 (1.001–1.002)<0.001Vitamin D (nmol/L)0.996 (0.992–1.000)0.047CRP (mg/dL)1.093 (1.031–1.158)0.003Ferritin ≥ 100 (ng/mL)1.037 (0.897–1.198)0.622Data presented as HR (95% CI). DM, diabetes; BMI: body mass index; FBG: fasting blood glucose; GFR: glomerular filtration rate; ACR: albuminuria creatinine ratio; CRP: C-reactive protein. Multivariate COX regression of 25-year survival in CKD after PSM. Data presented as HR (95% CI). DM, diabetes; BMI: body mass index; FBG: fasting blood glucose; GFR: glomerular filtration rate; ACR: albuminuria creatinine ratio; CRP: C-reactive protein. Association of AID and FID with mortality in CKD Anemia in those with CKD is multifactorial. According to the value of both ferritin and TSAT, we divided the anemia population into three groups: AID, FID, and the other causes of anemia. The characteristics of the FID, AID, and other causes of anemia group are shown in Supplementary Table 3, with the CRP levels being significantly higher in the FID group than those in the AID (p < 0.001) and other causes of anemia (p < 0.001) group. Kaplan–Meier analysis showed significantly different mortality rates between the three groups (Figure 3(A) before PSM; B after PSM). CKD patients with FID had the highest risk of mortality among the four groups (FID vs. the other three groups, p < 0.05), however, patients with AID had a mortality rate similar to those without anemia in the PSM cohort (AID vs. non-anemia, p > 0.05). The detailed results of the pairwise comparison are shown in Table 5. Similarly, FID and other causes of anemia were associated with a higher mortality rate in the multivariate Cox analysis (Supplementary Table 4, p = 0.010 for FID, p = 0.005 for the other causes of anemia). Kaplan–Meier analysis of all-cause mortality of CKD patients stratified by different types of anemia, (A) 25-year all-cause mortality, p < 0.001; (B) 25-year all-cause mortality in the PSM cohort (n = 573 pairs, matching for eGFR, age, and gender), p < 0.001. Table 5.The pairwise comparison of the Kaplan–Meier curves between different subtypes of anemia. Before PSMAfter PSM p Valuep ValueNon-anemia vs. AID0.1540.295Non-anemia vs. FID<0.001<0.001Non-anemia vs. others<0.001<0.001AID vs. FID<0.001<0.001AID vs. others<0.001<0.001FID vs. others<0.0010.002AID: absolute iron deficiency; FID: functional iron deficiency; others, other causes of anemia. The pairwise comparison of the Kaplan–Meier curves between different subtypes of anemia. AID: absolute iron deficiency; FID: functional iron deficiency; others, other causes of anemia. Discussion This study evaluated the correlation of anemia, especially iron deficiency anemia, with mortality in the prospective cohort of non-dialysis dependent CKD population. Our study demonstrates that anemia was associated with all-cause mortality in patients with CKD; CKD patients with FID had the highest risk of mortality; Patients with AID had a mortality rate similar to those without anemia. This study may shed light on the importance of the underlying causes of FID in CKD and suggest that correction of the underlying causes of FID anemia, such as inflammation and malnutrition, is critical in managing patients with CKD. The present study found nearly 60% of CKD anemia patients had either AID (38.8%) or FID (19.8%). This result is in accordance with a previous study [15] reported that among those anemia patients whose eGFR < 60 mL/min/1.73m2, 30% of them had AID and 19% had FID. Several demographic and comorbid factors were associated with AID and FID [16]. Wong et al. [17] found that the prevalence of iron deficiency anemia among patients with CKD varied across countries, but not appreciably across stages of CKD. We did not repeatedly analyze the prevalence of iron deficiency anemia in the different stages of CKD, as HSU CY et al. [4] had previously reported the prevalence of TSAT < 20% and ferritin <100 ng/mL among advanced CKD (creatinine clearance of 20–30 mL/min) patients using the same NHANES dataset. The present study demonstrated that anemia was an independent risk factor for all-cause mortality in CKD patients. This finding was in line with the well-documented studies demonstrating anemia in CKD is associated with reduced health-related quality of life, increased risk of CKD progression, and all-cause mortality [7, 16, 18]. Studies examining the associations of iron deficiency anemia with outcomes in patients with non-dialysis-dependent CKD are limited. A recent study by Awan et al. [15] analyzed the data from the US Veterans Administration and found that in non-dialysis dependent CKD patients, FID was associated with an increased risk of mortality and cardiovascular hospitalization, while AID was only associated with an increased risk of cardiovascular hospitalization but not mortality. Consistently, in the NHANCE III cohort, we also found that FID was associated with a higher risk of all-cause mortality among CKD patients, while AID was not. The underlying mechanism is not very clear but the impaired utilization of iron and/or systemic inflammation in FID are very likely the explanation [19, 20]. Chronic inflammation is highly prevalent in CKD patients. Consistent inflammation results in anemia through multiple pathways, one of the most important ones is iron utilization disorders. The IL-6 and bone morphogenetic protein-mediated increase in hepcidin expression lead to iron trapping within the macrophages and enterocytes, thus impair iron utilization by red blood cells [21]. Our data revealed that the FID anemia group had the highest level of CRP among the three subgroups of anemia. Cox multivariate regression analysis also suggested that both FID and CRP levels were associated with a higher mortality rate. However, Serum CRP is more of a biomarker for acute infection [22], and the sensitivity of CRP for detecting chronic inflammation remains debatable. More research is needed to investigate the relationship between CRP as a representation of chronic inflammation and FID. Anemia needs to be corrected appropriately for it contributes to a higher risk of mortality in CKD patients. Iron repletion is required for effective Hemoglobin synthesis. The 2012 KDIGO Guidelines on anemia management in CKD suggest treating anemia with iron supplementation in adult CKD stage 3–5 patients when TSAT is <30% and ferritin is <500 ng/mL. Compared to oral iron, intravenous (IV) iron therapy was more effective in increasing Hb [23] despite their impact on inflammation [24] or the incidence of composite cardiovascular AEs [25, 26] remains debatable. IV iron formulations such as ferric pyrophosphate citrate could even donate iron directly to transferrin and avoid iron sequestration in the reticuloendothelial macrophages [27], thus improving FID. However, supplementing iron without correcting the underlying causes of FID sometimes cannot achieve an ideal therapeutical effect. In that case, novel agents, such as the hypoxia-inducible factor proline hydroxylase inhibitor (HIF-PHI) have attracted much attention. Studies have revealed that HIF-PHI can promote the production of erythropoietin (EPO), downregulate the levels of hepcidin and ferritin [28], thus increasing the utilization of iron, and finally improving anemia in CKD patients. HIF-PHI combined with iron supplementation would be one of the promising alternate treatments, especially for FID anemia patients who do not respond to iron repletion. However, more scientific evidence is needed. The present study did not find that anemia increased the risk of cardiovascular mortality compared with non-anemia CKD patients after propensity score matching. The association between iron deficiency anemia and cardiovascular mortality has previously been investigated based on the data of patients with heart failure (HF), who were more severe and frequently hospitalized [29, 30]. Our cohort is a general-population-based study. Different population characteristics may cause this discrepancy. Further study in CKD patients with more CVD risk factors is needed to evaluate the association between iron deficiency anemia and hard endpoints, including heart failure hospitalization and mortality. Our study was notable for its large sample size, its nationally representative nature, and long-term follow-up duration. Nevertheless, several limitations of our study should be addressed. First, there is growing evidence indicating that the traditional standard of TSAT and serum ferritin are not sensitive enough to detect iron deficiency [31, 32]. More alternative measures such as reticulocyte hemoglobin content, serum hepcidin, and percentage of hypochromic RBCs are needed to confirm the diagnosis of iron deficiency and differentiate FID and AID. Furthermore, some studies reported that those with ferritin >500 ng/mL and TSAT < 20% were associated with the highest risk of death [15]. In this study, the numbers with ferritin > 500 ng/mL and TSAT <20% were very small (n = 8), therefore, these patients were included in the FID without being classified as a separate group. Another limitation is that we lack data on iron supplementation, which may provide more information about the influence of oral or IV iron. In summary, anemia is associated with all-cause mortality in CKD patients, specifically, FID but not AID is associated with a higher mortality rate; pathological processes that block iron utilization may be an important cause of mortality. Our results have important implications for the current anemia management in CKD. The optimal iron supplements need to be further explored according to the status of serum ferritin in CKD. More randomized trials are needed to establish the efficacy and safety of iron repletion on hard endpoints, including mortality and heart failure hospitalization, especially in the CKD population. Novel available therapies for anemia of CKD including iron and noniron agents will probably provide more choices and benefits for this population. Supplementary Material Supplemental Material